Cangrelor New Standard for Large Vessel Occlusion Stroke with Equivalent traditional Outcomes, Study

While Endovascular Treatment (EVT) has significantly advanced stroke care, procedural failures and early reocclusions frequently occur due to underlying arterial wall disease, incomplete thrombus removal, or acute endothelial injury; although glycoprotein (GP) IIb/IIIa inhibitors have been extensively researched in these contexts, the comparative utility of the faster-acting cangrelor remained a significant clinical gap until Dr. Małgorzata Milnerowicz and the Endovascular Treatment in Ischemic Stroke (ETIS) investigators sought to evaluate both agents in patients with Large Vessel Occlusion Stroke (LVOS).

Therefore, the multicenter retrospective analysis evaluated data from 559 patients—comprising 160 receiving glycoprotein IIb/IIIa inhibitors and 399 treated with cangrelor—across 34 French centers between July 2018 and September 2023, specifically focusing on those with refractory occlusions or high reocclusion risks during emergency interventions. The research utilized propensity score overlap weighting to compare the primary endpoint of 90-day favorable functional outcomes against secondary measures such as intracranial hemorrhage (ICH), early neurological improvement, and day 1 arterial patency.

Key Clinical Findings of the Study Include:

• Comparable Functional Independence: The study identified that 43.7% of patients in the cangrelor group achieved favorable 90-day outcomes compared to 41.7% in the inhibitor cohort, indicating no significant difference in long-term recovery (OR=1.1; 95% CI 0.61 to 1.93).

• High Angiographic Success: Reperfusion efficacy was nearly identical between the two pharmacological strategies, as the study reported modified Thrombolysis in Cerebral Infarction (mTICI) scores of ≥2b in 90.1% of cangrelor cases and 89.5% for those receiving traditional inhibitors.

• Equivalent Safety Profiles: There were no meaningful disparities regarding procedural complications or serious adverse events, with the study noting that rates of symptomatic intracranial hemorrhage and 90-day mortality remained statistically similar across both treatment arms.

• Consistent Early Recovery: Initial neurological gains and day 1 arterial patency were maintained effectively by both agents, confirming the study's finding that neither drug held a distinct advantage in immediate post-procedural vessel stability.

The results suggest that cangrelor provides a safe and effective adjunctive option for complex stroke management, yielding a 90.1% successful reperfusion rate and comparable 90-day functional independence when measured against conventional glycoprotein inhibitors.

These findings indicate that the unique pharmacodynamic properties of cangrelor make it a promising pharmacological tool for clinicians to consider during the acute management of difficult intracranial and extracranial large vessel occlusions.

Although the study provides robust comparative evidence, its retrospective design highlights a potential limitation, suggesting that future prospective trials could further validate these outcomes across more diverse clinical settings.

Reference

Milnerowicz M, Desilles JP, Pop R, Dargazanli C, Labreuche J, Sibon I, et al. Cangrelor versus GPIIb/IIIa inhibitors as adjunctive therapy in endovascular treatment of large vessel occlusion stroke. J NeuroIntervent Surg. 2024;18(4).